DevOps Engineer - USA
About the job
- At least 2 years of experience in a DevOps, Infrastructure, or Site Reliability Engineering role within a Linux-centric environment.
- Strong hands-on experience managing Kubernetes environments and deploying workloads.
- Experience building and scaling continuous integration and continuous delivery pipelines, such as GitLab CI or similar tools.
- Proficiency with Linux system administration, shell scripting, and configuration-driven tooling.
- Familiarity with observability platforms such as Prometheus, Grafana, and the ELK stack.
- Ability to collaborate across technical teams in a fast-paced environment.
- Manage and optimize Kubernetes environments and workload deployments.
- Design, build, and maintain continuous integration and continuous delivery pipelines supporting diverse technical workloads.
- Implement automated configuration strategies to standardize operational practices and improve delivery speed.
- Develop internal tools and automation to simplify infrastructure provisioning, monitoring, and management.
- Partner with Linux Systems Engineers and internal technical stakeholders to align delivery pipelines with operational goals.
- Maintain observability tooling for monitoring and logging.
- Author technical documentation to establish scalable best practices.
- Prior experience supporting quantitative research, trading platforms, or high-performance computing environments.
About the company
Trexquant is a quantitative finance firm that builds multi-asset portfolios using machine learning. It develops investment and research tools that ingest a wide range of data variables to create complex trading models and strategies, which in turn generate trading signals. These signals guide decisions across global markets. The product works by applying advanced machine learning to large datasets to create predictive models and rule-based strategies, which drive portfolio construction and trading actions through the firm’s platform. Trexquant differentiates itself by emphasizing the breadth of data it uses and the depth of machine-learning driven models to craft multi-asset portfolios, aiming to produce signals that outperform global market conditions. The company’s goal is to generate investment performance that beats benchmarks by using data-driven signals and diversified, multi-asset strategies.
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
Stamford, Connecticut
Founded
2012
Get referred to Trexquant
See people who can refer or advise you
Simplify's Take
What believers are saying
- On January 13, 2026, Trexquant announced a New York City office for Fall 2026.
- Trexquant Careers posted a September 5, 2026 opening for Head of Systematic Macro Strategy.
- Oxford Ledge tracked Q1 2026 holdings growth to $13.8 billion, up 23.2% quarter-over-quarter.
What critics are saying
- Trexquant competes with Citadel, Man Group, and Two Sigma for scarce quant researchers.
- Alpha decay and crowding can erase statistical-arbitrage edges within months after signal discovery.
- A 2026 drawdown would trigger redemptions, compress fees, and threaten Trexquant's franchise.
What makes Trexquant unique
- Trexquant's TREX QUANTA platform unifies research, simulation, and collaboration for alpha development.
- The firm runs market-neutral global equity portfolios using machine learning and data science.
- Its Q1 2026 13F reported 1,561 positions and $13.8 billion in equities.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Pre-Tax Commuter Benefits
Performance Bonus
Company News
Trexquant Investment LP bought a new position in The Mosaic Company (NYSE:MOS – Free Report) in the 1st quarter, HoldingsChannel.com reports. The firm bought 46,193 shares of the basic materials company’s stock, valued at approximately $1,248,000. Several other institutional investors have also recently made changes to their positions in MOS. NBC Securities Inc. bought a […]
Trexquant Investment LP purchased a new stake in Sinclair in the 4th quarter worth approximately $1,688,000.
Finally, Trexquant Investment LP acquired a new stake in Korro Bio in the fourth quarter worth about $211,000.
Trexquant Investment LP purchased a new stake in Phathom Pharmaceuticals in the 4th quarter worth $3,075,000.
Finally, Trexquant Investment LP purchased a new stake in iShares Core S&P U.S. Growth ETF during the fourth quarter worth approximately $222,000.